glp-1 and dpp4 DPP-4 inhibitors GLP-1RAs: cardiovascular safety and benefits GLP-1-RA and DPP-4 inhibitors in
Description
Urinary tract infections are not listed among the recognised adverse effects in the Summary of Product Characteristics (SmPC) for Wegovy, nor were they identified as a significant safety signal in the pivotal STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme involving over 4,500 participants
Consent Written consent was obtained by the principal investigators A.J
For questions, please feel free to Contact Us
[DOI] [PubMed] [Google Scholar] 112.Huang X, et al
The most common side effects reported by patients are mild to moderate gastrointestinal symptoms, such as nausea, vomiting, diarrhea, and constipation
